Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ALLO - Allogene: Speculative CAR T Biotech With Big Potential In Oncology

ALLO - Allogene: Speculative CAR T Biotech With Big Potential In Oncology

Allogene Therapeutics Inc.
  • ALLO-316 was given Fast Track Designation for the treatment of patients with renal cell carcinoma.
  • It is expected that the global kidney cancer market could reach $9.4 billion by 2026.
  • ALLO-647 is a lymphodepletion agent that Allogene has developed to possibly help the expansion and persistence of many of its CAR Ts in its pipeline.
  • The TurboCAR technology was incorporated into ALLO-605, which is being used for the treatment of patients with multiple myeloma.

For further details see:

Allogene: Speculative CAR T Biotech With Big Potential In Oncology
Stock Information
Company Name: Allogene Therapeutics Inc.
Stock Symbol: ALLO
Market: NASDAQ
Website: allogene.com
Menu
ALLO ALLO Quote ALLO Short ALLO News ALLO Articles ALLO Message Board
Get ALLO Alerts

News, Short Squeeze, Breakout and More Instantly...